883560-06-3

Basic information

• Product Name: 2-[4-(4-chloro-phenoxy)-phenyl]-3H-imidazo[4,5-b]pyridine-6-carbonitrile
• Synonyms: 2-[4-(4-chloro-phenoxy)-phenyl]-3H-imidazo[4,5-b]pyridine-6-carbonitrile
• CAS NO: 883560-06-3
• Molecular Weight: 346.776
• Mol File: 883560-06-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-[4-(4-chloro-phenoxy)-phenyl]-3H-imidazo[4,5-b]pyridine-6-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[4-(4-chloro-phenoxy)-phenyl]-3H-imidazo[4,5-b]pyridine-6-carbonitrile(883560-06-3)
• EPA Substance Registry System: 2-[4-(4-chloro-phenoxy)-phenyl]-3H-imidazo[4,5-b]pyridine-6-carbonitrile(883560-06-3)

Safety Data

• Hazardous Substances Data: 883560-06-3(Hazardous Substances Data)

Upstream product

• 38875-53-5 5-bromo-pyridine-2,3-diamine 
• 61343-99-5 4-(4'-chlorophenoxy)benzaldehyde 
• 6945-68-2 5-bromo-3-nitro-pyridin-2-ylamine 
• 1003711-13-4 6-amino-5-nitronicotinonitrile 
• 107238-27-7 5,6-diaminonicotinonitrile 

Relevant articles and documents

Methods for Chk2 inhibitor patient selection

The present invention contemplates a method to identify subjects that either have a tumor, or are at risk for tumor development, that are responsive to various inhibitors of an activated-Chk2 protein. Such Chk2 inhibitors may comprise a benzimidazole core structure, and derivatives thereof. Other Chk2 inhibitors may comprise nucleic acids, such as silencing interference RNA's specific for a Chk2 expression. Other Chk2 inhibitors may comprises proteins, such as antibodies. For example, the present invention contemplates that when a Chk2 inhibitor is administered during, or after, ionizing radiation tumor cell apoptosis is increased.